Priavoid attends the Prion 2022 conference in Göttingen, Germany, between September 13 and 16, with a large delegation. Please, stop by at our booth! We are looking forward to four days of great talks and a lot of exchange with the scientific community.
About Priavoid GmbH:
Priavoid GmbH is a clinical-stage drug developer. The company develops novel all-D-peptide drug candidates for the treatment of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, ALS (amyotrophic lateral sclerosis) or tauopathies. All drug candidates are designed with an anti-prionic mechanism of action to dissolve neurotoxic protein aggregates. Priavoid is a spin-off of Heinrich Heine University Düsseldorf and Research Center Jülich and was founded in 2017. The company is privately financed, including by Qiagen co-founder Prof. em. Dr. Dr. h.c. Detlev Riesner.